Dr. Conor Ernst Steuer, MD

Dr. Steuer practices at Emory University Hospital Midtown in Atlanta, Georgia, part of Emory University.

Dr. Steuer's NPI, 1386888220, was assigned on April 22, 2009. Dr. Steuer graduated from New York University School of Medicine in 2009. Dr. Steuer holds Georgia license 068312.

Dr. Steuer's primary practice is Emory University Hospital Midtown, at 550 Peachtree Street, NE, Atlanta, GA 30308 in Fulton County. The practice phone is (404) 686-2450.

Dr. Steuer's primary practice is Emory University Hospital Midtown in Atlanta, Georgia, part of Emory University. Dr. Steuer is also affiliated with Emory University Hospital. The medical group on file is Emory Clinic. Dmand AI also links Dr. Steuer to 1 more hospital, 1 clinical lab and 1 home health agency, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Steuer practices, 5 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Steuer's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Steuer is licensed in Georgia.

CMS data shows 155 Medicare services from Dr. Steuer across 3 procedure codes in 2024, all of them office visits, for 123 Medicare patients. Medicare paid $11,536 for them.

CMS counts 123 Medicare patients who saw Dr. Steuer in 2024. The largest group is 65 to 74, with 69 patients. 75% of them have high blood pressure, and 66% have high cholesterol. 15% are also on Medicaid. Their average risk score is 2.19, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Steuer's median patient age at 72, with 48% women.

In 2024, Dr. Steuer wrote 811 Medicare Part D claims for 144 patients. 70% of them were for generic drugs. CMS names the drug for 675 of them, across 15 drugs with 11 or more claims each, at $2,847,441 in total drug cost. In 2023, CMS named 582 claims across 18 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 95 out of 100 for Dr. Steuer for performance year 2024, reported through an alternative payment model (APM). Dr. Steuer accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Steuer as offering telehealth.

Dmand AI links 97 papers to Dr. Steuer, published from 2013 to 2025. 2020 was the busiest year, with 13. The most frequent topics are Lung Neoplasms, Head and Neck Neoplasms and Carcinoma, Non-Small-Cell Lung. Dr. Steuer has published most often in Cancer. Dr. Steuer's most frequent co-authors are Suresh Sakkarai Ramalingam, MD, Nabil F. Saba, MD and Mihir R. Patel.

Dmand AI links Dr. Steuer to 11 clinical trials, 3 of them phase 1/2 studies. 8 are still active or recruiting. Conditions studied include Carcinoma, Medullary, Thyroid Cancer, Papillary and Carcinoma, Non-Small-Cell Lung. National Cancer Institute (NCI) sponsors the most, 3. Open Payments lists research payments to Dr. Steuer that name 1 trial.

CMS Open Payments shows 97 general payments to Dr. Steuer from 19 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 75% of the total. Novocure Inc. paid the most, $22,736. It also lists 3 research payments totaling $41,807 from 2020 to 2022, naming 1 clinical trial.

Dr. Steuer graduated from New York University School of Medicine in 2009.